Somaxon Pharmaceuticals (SOMX) says it's entered into a settlement agreement with Actavis Elizabeth LLC and Actavis to resolve four patent litigation suits involving its Silenor 3 mg and 6 mg tablets. The settlement grants Somaxon an additional seven years protection on its patent, allowing Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. Shares +12% AH.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs